Filing Details
- Accession Number:
- 0001209191-23-048467
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-06 17:33:29
- Reporting Period:
- 2023-09-01
- Accepted Time:
- 2023-09-06 17:33:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1649094 | Vaxcyte Inc. | PCVX | Biological Products, (No Disgnostic Substances) (2836) | 464233385 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1813798 | Jim Wassil | C/O Vaxcyte, Inc. 825 Industrial Road, Ste. 300 San Carlos CA 94070 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-09-01 | 3,000 | $2.42 | 173,066 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-09-01 | 2,677 | $52.75 | 170,389 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-09-01 | 323 | $53.36 | 170,066 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-09-05 | 2,131 | $51.00 | 167,935 | No | 4 | F | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | F | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2023-09-01 | 3,000 | $0.00 | 3,000 | $2.42 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
113,555 | 2029-12-16 | No | 4 | M | Direct |
Footnotes
- Includes 1,040 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2023.
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $52.27 to $53.19. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $53.28 to $53.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
- 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.